Exact Mass: 841.4221494000001

Exact Mass Matches: 841.4221494000001

Found 34 metabolites which its exact mass value is equals to given mass value 841.4221494000001, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

CDP-DG 24:0

1,2-Didodecanoyl-sn-glycero-3-cytidine-5-diphosphate

C36H65N3O15P2 (841.389072)

CDP-DG(i-12:0/i-12:0)

({[(2R)-2,3-bis[(10-methylundecanoyl)oxy]propoxy](hydroxy)phosphoryl}oxy)({[(2R,3R,5R)-3,4-dihydroxy-5-(2-hydroxy-4-imino-1,4-dihydropyrimidin-1-yl)oxolan-2-yl]methoxy})phosphinate

C36H65N3O15P2 (841.389072)

CDP-DG(i-12:0/i-12:0) is a cytidine diphosphate diacylglycerol or CDP-diacylglycerol (CDP-DG). CDP-diacylglycerol is an important branchpoint intermediate in eukaryotic phospholipid biosynthesis and could be a key regulatory molecule in phospholipid metabolism. It is a glycerophospholipid in which a cytidine diphosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, CDP-diacylglycerols can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. CDP-DG(i-12:0/i-12:0), in particular, consists of one chain of isododecanoic acid at the C-1 position and one chain of isododecanoic acid at the C-2 position. Cytidine diphosphate diacylglycerols are rarely noticed in analyses of lipid compositions of tissues, as they are present is such small amounts (perhaps only 0.05\\% or so of the total phospholipids).

TUBULYSIN

4-[({2-[1-(acetyloxy)-3-(2-{[hydroxy(1-methylpiperidin-2-yl)methylidene]amino}-3-methyl-N-{[(3-methylbutanoyl)oxy]methyl}pentanamido)-4-methylpentyl]-1,3-thiazol-4-yl}(hydroxy)methylidene)amino]-2-methyl-5-(4-methylphenyl)pentanoate

C44H67N5O9S (841.4659252)

Carbomycin

Leucomycin V,9-deoxy-12,13-epoxy-12,13-dihydro-9-oxo-, 3-acetate 4B-(3-methylbutanoate),(12S,13S)-

C42H67NO16 (841.4459621999999)

D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007933 - Leucomycins

1,2-Didodecanoyl-sn-glycero-3-cytidine 5-diphosphate

C36H65N3O15P2 (841.389072)

A CDP-diacylglycerol in which the acyl groups at positions 1 and 2 are specified as dodecanoyl.

CID 10350561

C42H67NO16 (841.4459621999999)

D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007933 - Leucomycins

4-[[2-[1-Acetyloxy-4-methyl-3-[3-methylbutanoyloxymethyl-[3-methyl-2-[(1-methylpiperidine-2-carbonyl)amino]pentanoyl]amino]pentyl]-1,3-thiazole-4-carbonyl]amino]-2-methyl-5-(4-methylphenyl)pentanoic acid

4-[[2-[1-Acetyloxy-4-methyl-3-[3-methylbutanoyloxymethyl-[3-methyl-2-[(1-methylpiperidine-2-carbonyl)amino]pentanoyl]amino]pentyl]-1,3-thiazole-4-carbonyl]amino]-2-methyl-5-(4-methylphenyl)pentanoic acid

C44H67N5O9S (841.4659252)

N-[(E)-1-[5-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxytridec-4-en-2-yl]octanamide

C39H71NO18 (841.4670905999999)

N-[(E)-1-[5-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxyundec-4-en-2-yl]decanamide

C39H71NO18 (841.4670905999999)

N-[(E)-1-[5-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxyoct-4-en-2-yl]tridecanamide

C39H71NO18 (841.4670905999999)

N-[(E)-1-[5-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxypentadec-4-en-2-yl]hexanamide

C39H71NO18 (841.4670905999999)

(Z)-N-[1-[5-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxyoctan-2-yl]tridec-9-enamide

C39H71NO18 (841.4670905999999)

N-[(E)-1-[5-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxyhexadec-4-en-2-yl]pentanamide

C39H71NO18 (841.4670905999999)

N-[(E)-1-[5-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxydodec-4-en-2-yl]nonanamide

C39H71NO18 (841.4670905999999)

N-[(E)-1-[5-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxynon-4-en-2-yl]dodecanamide

C39H71NO18 (841.4670905999999)

N-[(E)-1-[5-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxyoctadec-4-en-2-yl]propanamide

C39H71NO18 (841.4670905999999)

N-[(E)-1-[5-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxydec-4-en-2-yl]undecanamide

C39H71NO18 (841.4670905999999)

N-[(E)-1-[5-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxyheptadec-4-en-2-yl]butanamide

C39H71NO18 (841.4670905999999)

N-[(E)-1-[5-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxynonadec-4-en-2-yl]acetamide

C39H71NO18 (841.4670905999999)

N-[(E)-1-[5-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxytetradec-4-en-2-yl]heptanamide

C39H71NO18 (841.4670905999999)

BiotinylPE(27:3)

BiotinylPE(10:3_17:0)

C42H72N3O10PS (841.4675782)

CDP-DG 12:0/12:0

C36H65N3O15P2 (841.389072)

LNAPS 40:11;O

C46H68NO11P (841.4529748)

PS 18:4/22:7;O

C46H68NO11P (841.4529748)

PS 40:11;O

C46H68NO11P (841.4529748)

cyclo(RLsKDK) (TFA)

C33H58F3N11O11 (841.4269154)

cyclo(RLsKDK) (TFA) (BK-1361 (TFA)) is a specific inhibitor of metalloproteinase ADAM8 with an IC50 value of 182 nM. cyclo(RLsKDK) (TFA) has potential applications in inflammatory diseases and cancer[1].

3-[(3s,6r,9z,12s,15s,16r)-3-[(2s)-butan-2-yl]-9-ethylidene-5,8,11,14-tetrahydroxy-15-{[(2s)-1-hydroxy-2-{[(2s)-1-hydroxy-2-{[(2e)-1-hydroxy-2-methylbut-2-en-1-ylidene]amino}-3-methylbutylidene]amino}-3-(4-hydroxyphenyl)propylidene]amino}-12,16-dimethyl-2-oxo-1-oxa-4,7,10,13-tetraazacyclohexadeca-4,7,10,13-tetraen-6-yl]propanoic acid

3-[(3s,6r,9z,12s,15s,16r)-3-[(2s)-butan-2-yl]-9-ethylidene-5,8,11,14-tetrahydroxy-15-{[(2s)-1-hydroxy-2-{[(2s)-1-hydroxy-2-{[(2e)-1-hydroxy-2-methylbut-2-en-1-ylidene]amino}-3-methylbutylidene]amino}-3-(4-hydroxyphenyl)propylidene]amino}-12,16-dimethyl-2-oxo-1-oxa-4,7,10,13-tetraazacyclohexadeca-4,7,10,13-tetraen-6-yl]propanoic acid

C41H59N7O12 (841.4221494000001)

3-[(9z)-9-ethylidene-5,8,11,14-tetrahydroxy-15-({1-hydroxy-2-[(1-hydroxy-2-{[(2e)-1-hydroxy-2-methylbut-2-en-1-ylidene]amino}-3-methylbutylidene)amino]-3-(4-hydroxyphenyl)propylidene}amino)-12,16-dimethyl-3-(2-methylpropyl)-2-oxo-1-oxa-4,7,10,13-tetraazacyclohexadeca-4,7,10,13-tetraen-6-yl]propanoic acid

3-[(9z)-9-ethylidene-5,8,11,14-tetrahydroxy-15-({1-hydroxy-2-[(1-hydroxy-2-{[(2e)-1-hydroxy-2-methylbut-2-en-1-ylidene]amino}-3-methylbutylidene)amino]-3-(4-hydroxyphenyl)propylidene}amino)-12,16-dimethyl-3-(2-methylpropyl)-2-oxo-1-oxa-4,7,10,13-tetraazacyclohexadeca-4,7,10,13-tetraen-6-yl]propanoic acid

C41H59N7O12 (841.4221494000001)

3-[(3s,6r,9z,12s,15s,16r)-9-ethylidene-5,8,11,14-tetrahydroxy-15-{[(2s)-1-hydroxy-2-{[(2s)-1-hydroxy-2-[(1-hydroxy-3-methylbut-2-en-1-ylidene)amino]-3-methylbutylidene]amino}-3-(4-hydroxyphenyl)propylidene]amino}-12,16-dimethyl-3-(2-methylpropyl)-2-oxo-1-oxa-4,7,10,13-tetraazacyclohexadeca-4,7,10,13-tetraen-6-yl]propanoic acid

3-[(3s,6r,9z,12s,15s,16r)-9-ethylidene-5,8,11,14-tetrahydroxy-15-{[(2s)-1-hydroxy-2-{[(2s)-1-hydroxy-2-[(1-hydroxy-3-methylbut-2-en-1-ylidene)amino]-3-methylbutylidene]amino}-3-(4-hydroxyphenyl)propylidene]amino}-12,16-dimethyl-3-(2-methylpropyl)-2-oxo-1-oxa-4,7,10,13-tetraazacyclohexadeca-4,7,10,13-tetraen-6-yl]propanoic acid

C41H59N7O12 (841.4221494000001)

(2s)-2-({[(3s,9s,12s,15r)-12-[(2s)-butan-2-yl]-2,5,11,14-tetrahydroxy-9-[2-(4-hydroxyphenyl)ethyl]-7-methyl-8-oxo-3-(2-phenylethyl)-1,4,7,10,13-pentaazacyclononadeca-1,4,10,13-tetraen-15-yl]-c-hydroxycarbonimidoyl}amino)-3-phenylpropanoic acid

(2s)-2-({[(3s,9s,12s,15r)-12-[(2s)-butan-2-yl]-2,5,11,14-tetrahydroxy-9-[2-(4-hydroxyphenyl)ethyl]-7-methyl-8-oxo-3-(2-phenylethyl)-1,4,7,10,13-pentaazacyclononadeca-1,4,10,13-tetraen-15-yl]-c-hydroxycarbonimidoyl}amino)-3-phenylpropanoic acid

C45H59N7O9 (841.4374044000001)

2-[({3-benzyl-2,5,11,14-tetrahydroxy-9-[2-(4-hydroxyphenyl)ethyl]-6,7-dimethyl-8-oxo-12-(sec-butyl)-1,4,7,10,13-pentaazacyclononadeca-1,4,10,13-tetraen-15-yl}-c-hydroxycarbonimidoyl)amino]-3-phenylpropanoic acid

2-[({3-benzyl-2,5,11,14-tetrahydroxy-9-[2-(4-hydroxyphenyl)ethyl]-6,7-dimethyl-8-oxo-12-(sec-butyl)-1,4,7,10,13-pentaazacyclononadeca-1,4,10,13-tetraen-15-yl}-c-hydroxycarbonimidoyl)amino]-3-phenylpropanoic acid

C45H59N7O9 (841.4374044000001)